CN1177832C - 作为骨重吸收抑制剂和作为细胞粘附抑制剂的新的磺酰胺衍生物 - Google Patents

作为骨重吸收抑制剂和作为细胞粘附抑制剂的新的磺酰胺衍生物 Download PDF

Info

Publication number
CN1177832C
CN1177832C CNB998040894A CN99804089A CN1177832C CN 1177832 C CN1177832 C CN 1177832C CN B998040894 A CNB998040894 A CN B998040894A CN 99804089 A CN99804089 A CN 99804089A CN 1177832 C CN1177832 C CN 1177832C
Authority
CN
China
Prior art keywords
alkyl
group
aryl
formula
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998040894A
Other languages
English (en)
Chinese (zh)
Other versions
CN1293662A (zh
Inventor
A
A·佩曼
ά
D·W·维尔
J·克诺勒
K·舍伊尼曼
D·卡尼尔托
��ŷ��ά��
J·-F·古尔维斯特
¿
T·加德克
R·麦多维尔
S·C·波达赖
�������ɭ
R·A·库斯博特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EVENTIS PHARMACEUTICALS DEUTSCHE GmbH
Genentech Inc
Original Assignee
EVENTIS PHARMACEUTICALS DEUTSCHE GmbH
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EVENTIS PHARMACEUTICALS DEUTSCHE GmbH, Genentech Inc filed Critical EVENTIS PHARMACEUTICALS DEUTSCHE GmbH
Publication of CN1293662A publication Critical patent/CN1293662A/zh
Application granted granted Critical
Publication of CN1177832C publication Critical patent/CN1177832C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12Nitrogen atoms not forming part of a nitro radical
    • C07D239/16Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CNB998040894A 1998-01-23 1999-01-16 作为骨重吸收抑制剂和作为细胞粘附抑制剂的新的磺酰胺衍生物 Expired - Fee Related CN1177832C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1248998A 1998-01-23 1998-01-23
US09/012,489 1998-01-23

Publications (2)

Publication Number Publication Date
CN1293662A CN1293662A (zh) 2001-05-02
CN1177832C true CN1177832C (zh) 2004-12-01

Family

ID=21755208

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998040894A Expired - Fee Related CN1177832C (zh) 1998-01-23 1999-01-16 作为骨重吸收抑制剂和作为细胞粘附抑制剂的新的磺酰胺衍生物

Country Status (25)

Country Link
EP (1) EP1049677A1 (ru)
JP (1) JP2002501054A (ru)
KR (1) KR20010034319A (ru)
CN (1) CN1177832C (ru)
AP (1) AP1269A (ru)
AR (1) AR014456A1 (ru)
AU (1) AU752882B2 (ru)
BG (1) BG104630A (ru)
BR (1) BR9907735A (ru)
CA (1) CA2318221A1 (ru)
EA (1) EA003102B1 (ru)
HR (1) HRP20000493A2 (ru)
HU (1) HUP0100520A3 (ru)
ID (1) ID26219A (ru)
IL (1) IL137423A0 (ru)
NO (1) NO318795B1 (ru)
NZ (1) NZ505613A (ru)
PL (1) PL341871A1 (ru)
SK (1) SK10632000A3 (ru)
TR (1) TR200002160T2 (ru)
TW (1) TWI247742B (ru)
UA (1) UA63990C2 (ru)
WO (1) WO1999037621A1 (ru)
YU (1) YU47200A (ru)
ZA (1) ZA99476B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1070707A1 (en) * 1999-07-21 2001-01-24 Aventis Pharma Deutschland GmbH 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
EP1108721A1 (en) 1999-12-15 2001-06-20 Aventis Pharma Deutschland GmbH Thienylalanine derivatives as inhibitors of cell adhesion
US20030199571A1 (en) * 1999-12-24 2003-10-23 Gordon Bruton (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
CN1938293A (zh) * 2004-03-24 2007-03-28 捷瑞尼股份公司 抑制血管发生的新化合物及其应用
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
WO2016097001A1 (en) 2014-12-17 2016-06-23 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032710A1 (en) * 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
JP3895792B2 (ja) * 1995-12-08 2007-03-22 プロスケリア・エス・ア・エス 骨形成促進剤

Also Published As

Publication number Publication date
AP1269A (en) 2004-04-03
HRP20000493A2 (en) 2001-06-30
KR20010034319A (ko) 2001-04-25
YU47200A (sh) 2002-11-15
HUP0100520A1 (hu) 2001-07-30
BR9907735A (pt) 2000-10-17
CA2318221A1 (en) 1999-07-29
PL341871A1 (en) 2001-05-07
TR200002160T2 (tr) 2001-07-23
HUP0100520A3 (en) 2002-11-28
EA200000785A1 (ru) 2001-02-26
EP1049677A1 (en) 2000-11-08
EA003102B1 (ru) 2002-12-26
UA63990C2 (ru) 2004-02-16
NZ505613A (en) 2002-11-26
NO20003765L (no) 2000-09-25
ZA99476B (en) 1999-08-05
WO1999037621A1 (en) 1999-07-29
AU2518199A (en) 1999-08-09
AP2000001863A0 (en) 2000-09-30
AR014456A1 (es) 2001-02-28
BG104630A (en) 2001-04-30
NO318795B1 (no) 2005-05-09
ID26219A (id) 2000-12-07
TWI247742B (en) 2006-01-21
JP2002501054A (ja) 2002-01-15
NO20003765D0 (no) 2000-07-21
IL137423A0 (en) 2001-07-24
AU752882B2 (en) 2002-10-03
CN1293662A (zh) 2001-05-02
SK10632000A3 (sk) 2001-02-12

Similar Documents

Publication Publication Date Title
CN1177832C (zh) 作为骨重吸收抑制剂和作为细胞粘附抑制剂的新的磺酰胺衍生物
CN1205191C (zh) 作为骨吸收抑制剂和玻连蛋白受体拮抗剂的新酰基胍衍生物
CN1158279C (zh) 作为血管紧张肽(1-7)受体兴奋剂的1-(p-噻吩基苄基)咪唑,其制备方法,其用途和含有它们的药物制剂
CN1183111C (zh) 环烷并吲哚和环烷并氮杂吲哚衍生物,其制备方法和含有它们的药物组合物
CN1054603C (zh) 三取代的苯基衍生物及含有该衍生物的药物组合物
CN1030251C (zh) 取代的4-(喹啉-2-基-甲氧基)苯乙酸衍生物的制备方法
CN1273466C (zh) 具有唑基的喹啉衍生物和喹唑啉衍生物
CN1186332C (zh) 新的甲状腺受体配位体及方法ⅱ
CN1072647C (zh) 新的骨吸收的抑制剂和玻连蛋白受体的拮抗药
CN1158254C (zh) 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸
CN1046725C (zh) 稠合的咪唑化合物,它们的制备和应用
CN1101816C (zh) 取代的嘌呤衍生物、其制备方法、应用以及含有它们的组合物
CN1016778B (zh) 螺-取代的戊二酸单酰胺
CN1193276A (zh) 氧化-角鲨烯环化酶抑制剂的降低血中胆甾醇的应用
CN87101285A (zh) 8-取代的-2-氨基-1,2,3,4-四氢化荼
CN1382144A (zh) 作为p38蛋白激酶的抑制剂的杂烷基氨基-取代的双环氮杂环类化合物
CN1471515A (zh) 作为β2-肾上腺素受体激动剂及PDE-4抑制剂的有效的化合物
CN1418194A (zh) 酰胺化合物及其用途
CN1036566A (zh) 1,3,4,5-四氢苯并[c,d]哚类化合物
CN1300281A (zh) 具有释放生长激素特性的化合物
CN1161340C (zh) 为玻连蛋白受体拮抗剂的苯并咪唑化合物
CN1107857A (zh) 环状氨基酸衍生物
CN1051733A (zh) 酰基辅酶a:胆甾醇基转移酶抑制剂
CN1033804A (zh) 新的抗心律失常剂及其制备方法
CN1055920C (zh) 烷基苯甲酰基胍衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee